Full Press Release Details
MIMEDX Appoints Ricci S. Whitlow as Chief Operating Officer
MIMEDX bolsters management team with 30+ year MedTech veteran with extensive operational leadership
MARIETTA, Ga., January 3, 2023 MiMedx Group, Inc. (Nasdaq: MDXG) ( MIMEDX or the Company ), a pioneer and leader in
placental biologics, today announced that it has appointed Ricci S. Whitlow as Chief Operating Officer, a role that will lead the efforts of the Company s manufacturing, supply chain, procurement, quality, and regulatory functions.
Ms. Whitlow joins MIMEDX from Catalent, where she most recently served as President, Clinical Supply Services.
We are happy to begin 2023 with
the addition of Ricci Whitlow to the MIMEDX leadership team, stated Todd Newton, MIMEDX interim Chief Executive Officer. The future of placental-based biomaterial products and innovation will increasingly migrate from the current Human
Cells, Tissues and Cellular and Tissue-Based Products (HCT/P s) regulatory landscape to either the device or biologics regulatory pathways. We also see greater operational complexity in the future as requirements migrate from Good Tissue
Practices (GTPs) to current Good Manufacturing Practices (cGMPs). As our growth goals depend on our ability to manage these changes, we identified the need for a talented and capable operational leader with a unique span of scientific, technology,
process and people-leadership expertise. We believe Ricci is this leader.
I am excited to be joining the MIMEDX team during this important
period in the Company s history, stated Ms. Whitlow. With MIMEDX s portfolio of best-in-class products and its rich product pipeline, the
opportunity for our products to help a variety of patients in a variety of ways is truly remarkable. MIMEDX s lifeblood begins with precious birth tissue and combines with decades of expertise and knowhow to make products that clinicians and a
growing number of patients rely upon. I look forward to working with my colleagues here to grow our operations and tackle the large and growing market opportunities we have in front of us, both today and in the future.
This role is absolutely critical to our long-term success, continued Mr. Newton. I look forward to working with Ricci to continue to
bring products to market and fulfill our mission of leveraging our placental biologics technology to help address large and growing unmet needs in medicine.
Prior to her role at Catalent, Ms. Whitlow s extensive career has included leadership roles at a number of MedTech companies, including Optinose,
LifeCell, Kinetic Concepts and Johnson & Johnson. Ms. Whitlow received her B.S. in Industrial Engineering from Texas A&M University and her M.B.A. from the NYU/LSE/HEC TRIUM program.
MIMEDX is a pioneer and leader in
placental biologics, developing and distributing placental tissue allografts to help address unmet clinical needs in multiple sectors of healthcare, including the Advanced Wound Care market as well as in surgical recovery settings. MIMEDX is also
focused on advancing a promising late-stage pipeline opportunity targeted at decreasing pain and improving function for patients with knee osteoarthritis. Our products are derived from human placental tissues and processed using our
proprietary methods, including the Company s own PURION process. We employ Current Good Tissue Practices, Current Good Manufacturing
Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.